keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis drugs

keyword
https://www.readbyqxmd.com/read/29681490/safety-and-efficacy-of-delayed-release-dimethyl-fumarate-in-pediatric-patients-with-relapsing-multiple-sclerosis-focus
#1
Raed Alroughani, Rajiv Das, Natasha Penner, Joe Pultz, Catherine Taylor, Satish Eraly
BACKGROUND: No therapies have been formally approved by the Food and Drug Administration for use in pediatric multiple sclerosis, a rare disease. OBJECTIVE: We evaluated the safety, efficacy, and pharmacokinetics of dimethyl fumarate in pediatric patients with multiple sclerosis. METHODS: FOCUS, a phase 2, multicenter study of patients aged 10 to 17 years with relapsing-remitting multiple sclerosis, comprised an eight-week baseline and 24-week treatment period; during treatment, patients received dimethyl fumarate (120 mg twice daily on days one to seven; 240 mg twice a day thereafter)...
March 22, 2018: Pediatric Neurology
https://www.readbyqxmd.com/read/29678888/bovine-spastic-syndrome-a-review
#2
REVIEW
Victoria Goeckmann, Sophie Rothammer, Ivica Medugorac
Bovine spastic syndrome (BSS) was described for the first time in 1941. The disease occurs in various-maybe even all-cattle breeds and is a chronic-progressive neuromuscular disorder that commonly affects cattle of at least three years of age. Typical clinical signs of the disease are clonic-tonic cramps of the hindlimbs that occur in attacks. Since BSS does not recover, affected animals can only be treated symptomatically by improving welfare conditions and management factors, or with physical therapy or drugs...
April 20, 2018: Veterinary Record
https://www.readbyqxmd.com/read/29677591/lifestyle-factors-and-multiple-sclerosis-a-population-based-incident-case-control-study
#3
Ibrahim Abdollahpour, Saharnaz Nedjat, Mohammad Ali Mansournia, Mohammad Ali Sahraian, Ingrid van der Mei
OBJECTIVE: Although low sun exposure, low vitamin D, and smoking are established risk factor of multiple sclerosis (MS), there is less evidence on the role of the other lifestyle factors. We examined the association of sun exposure, physical activity, drug abuse, and alcohol intake with MS. MATERIALS AND METHODS: This was population-based incident case-control study in Iran with 547 incident cases and 1057 general population controls (7/8/2013-17/2/2015). Logistic regression was used to analyse the data...
March 31, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29671656/interferon-beta-injection-site-reactions-in-patients-with-multiple-sclerosis
#4
Martina Maurelli, Roberto Bergamaschi, Ambra Antonini, Maria Concetta Fargnoli, Elisa Puma, Giulia Mallucci, Rocco Totaro, Giampiero Girolomoni
Interferon-beta (IFNβ) are effective treatments for relapsing multiple sclerosis. IFNβ treatment includes subcutaneous (sc) IFNβ-1b, intramuscular and sc IFNβ-1a, and sc pegylated IFNβ-1a (PEG-IFNβ-1a). PEG-IFNβ-1a offers the advantage of a prolonged duration of action with a less frequent administration (every 2 weeks) and a higher patient adherence. However, the use of subcutaneous interferons could be characterized by potential skin toxicity. Injection site reactions (ISRs), featured by erythema, edema, pain and pruritus, are the most common adverse reactions...
April 19, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29670407/first-episode-psychosis-as-the-initial-presentation-of-multiple-sclerosis-a-case-report
#5
Athena Enderami, Rose Fouladi, Seyed Hamzeh Hosseini
Background: Multiple sclerosis (MS) is an inflammatory disease that affects the central nervous system (CNS). MS with episode of psychosis is a rare entity, and to the best of our knowledge, no case has been reported from Iran till date. Case presentation: We report a case of MS with first-episode psychosis in a 27-year-old single man with no history of psychiatric disorder or drug abuse. The patient developed neurological symptoms after 3 months and was finally diagnosed as a case of MS...
2018: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/29667130/beneficial-effects-of-the-calcium-channel-blocker-ctk-01512-2-in-a-mouse-model-of-multiple-sclerosis
#6
Rodrigo B M Silva, Samuel Greggio, Gianina T Venturin, Jaderson C da Costa, Marcus V Gomez, Maria M Campos
Voltage-gated calcium channels (VGCCs) play a critical role in neuroinflammatory diseases, such as multiple sclerosis (MS). CTK 01512-2 is a recombinant version of the peptide Phα1β derived from the spider Phoneutria nigriventer, which inhibits N-type VGCC/TRPA1-mediated calcium influx. We investigated the effects of this molecule in the mouse model of experimental autoimmune encephalomyelitis (EAE). The effects of CTK 01512-2 were compared to those displayed by ziconotide-a selective N-type VGCC blocker clinically used for chronic pain-and fingolimod-a drug employed for MS treatment...
April 17, 2018: Molecular Neurobiology
https://www.readbyqxmd.com/read/29666985/induction-of-disease-remission-with-one-cycle-of-alemtuzumab-in-relapsing-remitting-ms
#7
Alexandra S Kocsik, David E Klein, Maryana Liedke, Ulrike W Kaunzner, Nancy M Nealon, Susan A Gauthier, Timothy Vartanian, Jai S Perumal
OBJECTIVE: To investigate a single-course treatment with alemtuzumab in patients with relapsing-remitting multiple sclerosis. METHODS: We performed a retrospective chart review of all patients diagnosed with RRMS who were treated with alemtuzumab at our MS center and who had at least 12 month follow-up since the first dose. Data on radiological and clinical relapse were collected for the 2 years prior to patients' first dose of alemtuzumab and were tracked until the time of analysis...
April 17, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29658620/impact-of-economic-sanctions-on-access-to-noncommunicable-diseases-medicines-in-the-islamic-republic-of-iran
#8
Mehrnaz Kheirandish, Vida Varahrami, Abbas Kebriaeezade, Abdol Majid Cheraghali
Background: It has been argued that economic sanctions and the economic crisis have adversely affected access to drugs. Aim: To assess the impact of economic sanctions on the Iranian banking system in 2011 and Central Bank in 2012 on access to and use of drugs for noncommunicable diseases (NCDs). Methods: An interrupted time series study assessed the effects of sanctions on drugs for diabetes (5 drug groups), asthma (5 drug groups), cancer (14 drugs) and multiple sclerosis (2 drugs)...
April 5, 2018: Eastern Mediterranean Health Journal, la Revue de Santé de la Méditerranée Orientale
https://www.readbyqxmd.com/read/29656742/pathogenesis-of-progressive-multifocal-leukoencephalopathy-and-risks-associated-with-treatments-for-multiple-sclerosis-a-decade-of-lessons-learned
#9
REVIEW
Eugene O Major, Tarek A Yousry, David B Clifford
Progressive multifocal leukoencephalopathy (PML) is a rare, devastating demyelinating disease of the CNS caused by the JC virus (JCV) that occurs in patients with compromised immune systems. Detection of PML in systemically immunocompetent patients with multiple sclerosis treated with natalizumab points to a role for this drug in the pathophysiology of PML. Emerging knowledge of the cellular and molecular biology of JCV infection and the pathogenesis of PML-including interplay of this common virus with the human immune system and features of natalizumab that might contribute to PML pathogenesis-provides new opportunities to monitor viral status and predict risk of JCV-associated disease...
May 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29656444/predicting-therapeutic-response-to-fingolimod-treatment-in-multiple-sclerosis-patients
#10
Bibiana Quirant-Sánchez, José V Hervás-García, Aina Teniente-Serra, Luis Brieva, Ester Moral-Torres, Antonio Cano, Elvira Munteis, María J Mansilla, Silvia Presas-Rodriguez, Juan Navarro-Barriuso, Cristina Ramo-Tello, Eva M Martínez-Cáceres
AIMS: Fingolimod, an orally active immunomodulatory drug for relapsing-remitting multiple sclerosis (RRMS), sequesters T cells in lymph nodes through functional antagonism of the sphingosine-1-phosphate receptor, reducing the number of potential autoreactive cells that migrate to the central nervous system. However, not all RRMS patients respond to this therapy. Our aim was to test the hypothesis that by immune-monitoring RRMS patient's leukocyte subpopulations it is possible to find biomarkers associated with clinical response to fingolimod...
April 15, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29652301/-the-results-of-an-open-comparative-retrospective-trial-of-the-course-of-multiple-sclerosis-during-treatment-with-infibeta-and-other-interferon-beta-bioanalogues-and-glatiramer-acetate
#11
F A Khabirov, T I Khaybullin, E V Granatov, S R Shakirzianova, N N Babicheva, O S Kochergina, E F Rakhmatullina, G M Akhmedova, L A Averyanova, M A Yakupov, Zh F Sabirov
AIM: To evaluate the efficacy and safety of the interferon beta-1b bioanalogue 'infibeta' in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. MATERIAL AND METHODS: The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29651709/-cannabinoid-therapy-in-practice
#12
REVIEW
T Rasche, D Emmert, C Stieber, M Mücke, R Conrad
BACKGROUND: In recent years, the media and scientists have shown increased interest in cannabis-based drugs. OBJECTIVES: Background information about cannabis-based drugs and their mechanism of action as well as discussion of possible applications as supportive therapy or in palliative medicine, respectively, are presented. MATERIALS AND METHODS: The recent literature was examined and evaluated. RESULTS: In many medical fields, we do not have sufficient evidence for the efficacy of cannabinoids...
April 12, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29645071/daclizumab-in-multiple-sclerosis
#13
REVIEW
F C Perez-Miralles
INTRODUCTION: Daclizumab is a monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, investigated as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The present review addresses how the drug was developed, the known mechanism of action of the drug and the up-to-date data of efficacy and safety. DEVELOPMENT: Daclizumab has shown superiority in prevention of relapses against placebo and low-dose interferon beta-1a at a level that puts it on par with the rest of current first-line drugs...
April 16, 2018: Revista de Neurologia
https://www.readbyqxmd.com/read/29645067/-new-drugs-for-the-treatment-of-multiple-sclerosis
#14
EDITORIAL
J Rio
No abstract text is available yet for this article.
April 16, 2018: Revista de Neurologia
https://www.readbyqxmd.com/read/29629575/adult-hospital-admissions-associated-with-multiple-sclerosis-in-finland-in-2004-2014
#15
Anna-Leena Pirttisalo, Jussi O T Sipilä, Merja Soilu-Hänninen, Päivi Rautava, Ville Kytö
INTRODUCTION: Treatment of multiple sclerosis (MS) has developed significantly and several new immunotherapeutic drugs have become available in Finland since 2004. We studied whether this is associated with changes in hospital admission frequencies and healthcare costs and whether admission rates due to infection have increased. METHODS: The national Care Register for Health Care was searched for all discharges from neurological, medical, surgical, neurosurgical and intensive care units with MS as a primary diagnosis or an auxiliary diagnosis for primary infection diagnosis in 2004-2014...
April 9, 2018: Annals of Medicine
https://www.readbyqxmd.com/read/29624084/recent-developments-in-interferon-based-therapies-for-multiple-sclerosis
#16
Laura Dumitrescu, Cris S Constantinescu, Radu Tanasescu
Multiple sclerosis (MS) is a chronic and disabling immune-mediated disease of the central nervous system. Beta-interferons are the first approved and still the most widely used first-line disease-modifying treatment in MS. Areas covered: Here we focus on recent developments in pharmacology and delivery systems of beta-interferons, and discuss their place within current state of the art therapeutic approaches. We briefly review the clinical trials for classical and PEGylated formulations, emphasizing effectiveness, safety concerns, and tolerability...
April 6, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29623914/heterozygous-carriers-of-galactocerebrosidase-mutations-that-cause-krabbe-disease-have-impaired-microglial-function-and-defective-repair-of-myelin-damage
#17
REVIEW
Nicole J Scott-Hewitt, Christopher J Folts, Mark D Noble
This review addresses two puzzling findings related to mutations in galactocerebrosidase (GALC) that cause Krabbe disease (KD), a severe lysosomal storage disorder characterized by extensive myelin damage in children with mutations in both GALC alleles. First, heterozygous carriers of KD-causing mutations, which include the biological parents of children with KD, exhibit increased risk for developing other diseases. Second, variants in the GALC locus increase the risk of developing multiple sclerosis (MS), another disease characterized by extensive myelin damage...
March 2018: Neural Regeneration Research
https://www.readbyqxmd.com/read/29618808/fibrinogen-in-neurological-diseases-mechanisms-imaging-and-therapeutics
#18
REVIEW
Mark A Petersen, Jae Kyu Ryu, Katerina Akassoglou
The blood coagulation protein fibrinogen is deposited in the brain in a wide range of neurological diseases and traumatic injuries with blood-brain barrier (BBB) disruption. Recent research has uncovered pleiotropic roles for fibrinogen in the activation of CNS inflammation, induction of scar formation in the brain, promotion of cognitive decline and inhibition of repair. Such diverse roles are possible in part because of the unique structure of fibrinogen, which contains multiple binding sites for cellular receptors and proteins expressed in the nervous system...
April 5, 2018: Nature Reviews. Neuroscience
https://www.readbyqxmd.com/read/29618273/cost-effectiveness-of-cladribine-tablets-alemtuzumab-and-natalizumab-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-with-high-disease-activity-in-england
#19
Robert Hettle, Gerard Harty, Schiffon L Wong
AIMS: Cladribine tablets is the first oral short-course treatment approved for highly active relapsing multiple sclerosis (MS). The Association of British Neurologists guidelines currently recommend two infusion therapies, alemtuzumab and natalizumab, to treat high disease activity relapsing remitting MS (HDA-RRMS). This analysis assessed the cost-effectiveness of cladribine tablets in HDA-RRMS compared with alemtuzumab and natalizumab, from the perspective of the National Health Service (NHS) in England...
April 5, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29610145/autologous-hematopoietic-stem-cell-transplantation-in-the-treatment-of-multiple-sclerosis
#20
Carolina A Rush, Harold L Atkins, Mark S Freedman
Multiple sclerosis (MS) is an autoimmune disorder that typically affects young people during their most productive years, causing irreversible damage and accumulation of disability. Treatments over time have had modest effects at completely controlling or suppressing disease activity, but are generally aimed at controlling early dominating inflammation that, over time, accumulates damage and leads to progressive disability. Some unfortunate patients are destined to deteriorate despite even newer and more effective agents because of the inability of these drugs to fully curb the inflammatory component of the disease...
April 2, 2018: Cold Spring Harbor Perspectives in Medicine
keyword
keyword
18958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"